AN2 Therapeutics, Inc.

NASDAQ:ANTX

Biotechnology

Healthcare
$4.95 +0.82%

+$0.04 today

Market cap
$187.82M
Beta
-0.98
P/E (TTM)
-4.9
EPS (TTM)
-$1.01
52W Low $1.00High $6.91

Volume 0.97M

Average 0.29M

ANTX Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

AN2 Therapeutics, Inc.NASDAQ: ANTX

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 11.5% from a year ago

Total equity stood at $81.76M at the end of Q1 FY2026, up 11.5% from a year earlier and up 54.1% from the prior quarter. Over 3 fiscal years it compounded at -17.8% a year.

Context

  • Total equity amounted to 93.4% of total assets at the end of Q1 FY2026, up 3.3 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +11.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$81.76M+54.1% QoQ
Last fiscal yearDec 2025
$53.06M-35.2% YoY
Year agoMar 2025
$73.33M+11.5% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.5%——
1 year-35.2%——
3-year CAGR-17.8%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
53.06M USD
Year-over-year change
-35.2%
4-year CAGR
-3.8%

Total Equity vs competitors

How ANTX compares with its peers on the latest reported figures

  • ANTX's Mar 2026 total equity of $81.76M is the 4th highest of the 6 companies compared; the peer median is $85.71M.
  • Its year-over-year change of +11.5% is the 5th highest of 6, against a peer median of +476.0%.
  • Total equity amounts to 93.4% of total assets for ANTX, versus a peer median of 72.7%.
ANTX Competitors Peer median
Total Equity for ANTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SABSSAB Biotherapeutics, Inc.Jun 2026$214.79M +1687.5%+69.6%90.2%
BOLDBoundless Bio, Inc.Mar 2026$86.38M -36.8%—61.3%
IBIOiBio, Inc.Jun 2026$85.71M +476.0%+77.3%86.5%
ANTXAN2 Therapeutics, Inc.Mar 2026$81.76M +11.5%-17.8%93.4%
QTTBQ32 Bio Inc.Mar 2026$46.31M +1253.8%—72.7%
VRCAVerrica Pharmaceuticals Inc.Mar 2026$16.06M +186.4%-14.8%41.4%
Peer median (excluding ANTX) $85.71M+476.0%+69.6%72.7%

Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents12.1M27.22M15.65M21.35M19.94M
Short-term Investments46.46M68.84M91.65M62.27M38.06M
Net Receivables001.4M300K900K
Inventory00000
Other Current Assets1.55M2.56M3.21M2.34M1.04M
Total Current Assets60.11M98.62M110.51M86.26M59.94M
Property, Plant & Equipment (Net)053K000
Goodwill00000
Intangible Assets00000
Long-term Investments3.49M3.22M27.19M5.02M2.01M
Tax Assets00000
Other Non-current Assets1.72M667K1.04M804K0
Total Non-current Assets5.21M3.94M28.24M5.83M2.01M
Total Assets65.32M102.56M138.74M92.09M61.95M
Account Payables1.06M2.12M2.68M3.32M3.02M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities330K6K4.69M2.47M3.28M
Total Current Liabilities3.4M7.19M14.04M10.24M8.72M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities13K2K00170K
Total Non-current Liabilities13K2K00170K
Total Liabilities3.41M7.19M14.04M10.24M8.89M
Common Stock00000
Retained Earnings(47.38M)(89.72M)(154.46M)(205.78M)(240.95M)
Accumulated OCI(27K)(374K)275K31K57K
Other Stockholders Equity00000
Minority Interest00000
Total Equity61.91M95.37M124.7M81.85M53.06M
Total Debt053K000
Net Debt(12.1M)(27.17M)(15.65M)(21.35M)(19.94M)

AN2 Therapeutics, Inc.

NASDAQ:ANTX

Intrinsic Alpha fair value

Locked

Current Price

$4.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.